Evidence map›Paper›PMID 38713463›Full record

ArticleJAMA network open2024

Multilevel Characteristics of Cumulative Symptom Burden in Young Survivors of Childhood Cancer.

Madeline R Horan, Deo Kumar Srivastava, Jaesung Choi, Kevin R Krull, Gregory T Armstrong, Kirsten K Ness, Melissa M Hudson, Justin N Baker, I-Chan Huang

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Incidence and predictors of immune checkpoint inhibitor treatment-related cognitive impairment in a racial and ethnic diverse population.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Madeline R HoranDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Deo Kumar SrivastavaDepartment of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.
Jaesung ChoiDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Kevin R KrullDepartment of Psychology and Biobehavioral Sciences, St Jude Children's Research Hospital, Memphis, Tennessee.
Gregory T ArmstrongDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Kirsten K NessDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Melissa M HudsonDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.
Justin N BakerDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California.
I-Chan HuangDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9M
Patient-Reported Outcomes Version of CTCAE involving Childhood Cancer SurvivorsR01CA238368 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, JUSTIN N, HUANG, I-CHAN · 2019 to 2023
$3.5M
Training in Pediatric Cancer Survivorship Outcomes and InterventionsT32CA225590 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Kevin R Krull · 2018 to 2026
$2.4M
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA238368NCI NIH HHS T32 CA225590NCI NIH HHS U01 CA195547
6 · The paper itself

Abstract

Importance: Symptom burden and its characteristics among survivors of pediatric cancers aged 8 to 18 years remain understudied. Objective: To examine the prevalence of symptom burden among young childhood cancer survivors and identify associations with sociodemographic, clinical, and psychological resilience skills, and health-related quality of life (HRQOL). Design, Setting, and Participants: A cross-sectional analysis using data collected from November 1, 2017, to January 31, 2019, in a survivorship clinic at a US-based comprehensive cancer center was conducted. Participants included 302 dyads of children aged 8 to 18 years who survived at least 5 years beyond diagnosis and their primary caregivers. Data analysis was performed from March 13, 2023, to February 29, 2024. Exposures: Diagnosis, caregiver-reported family conflict, self-reported caregiver anxiety, neighborhood-level social vulnerability, and survivor-reported meaning and purpose. Main Outcomes and Measures: Novel symptom-level burden, integrating the attributes of severity and daily activity interference using the pediatric version of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, global cumulative symptom burden, and HRQOL using the EuroQol-5D. Multinomial logistic regression identified characteristics associated with symptom burden; linear regression assessed symptom burden and HRQOL associations. Results: Among 302 survivors (mean [SD] age, 14.2 [2.9] years, mean [SD] time since diagnosis, 10.9 [2.9] years; 153 [50.7%] male), 186 (62.0%) had low, 77 (25.7%) moderate, and 37 (12.3%) high global cumulative symptom burden. Greater caregiver anxiety was associated with moderate (risk ratio [RR], 1.56; 95% CI, 1.09-2.24) global symptom burden. Greater neighborhood deprivation was associated with moderate global symptom burden (RR, 4.86; 95% CI, 1.29-18.26). Survivors with greater meaning/purpose were less likely to have moderate (RR, 0.42; 95% CI, 0.29-0.61) and high (RR, 0.27; 95% CI, 0.16-0.46) global symptom burden. The burden of individual symptoms displayed similar patterns. Low (Cohen d, -0.60; 95% CI, -0.87 to -0.32) and moderate/high (d, -0.98; 95% CI, -1.53 to -0.43) general pain, moderate/high numbness (d, -0.99; 95% CI, -1.69 to -0.29), and moderate/high worry (d, -0.55; 95% CI, -0.99 to -0.11) were associated with lower HRQOL. Conclusions and Relevance: In this cross-sectional study of young childhood cancer survivors, symptom burden was prevalent. Caregiver anxiety and disparity-related neighborhood factors were associated with greater symptom burden, whereas meaning and purpose was a protective factor. Greater specific symptom burden contributed to poorer HRQOL. The findings suggest that interventions targeting resilience and neighborhood adversity may alleviate symptom burden and improve HRQOL.

Indexed as

Cancer SurvivorsNeoplasmsQuality of LifeAdolescentAnxietyCaregiversChildCross-Sectional StudiesFemaleHumansMaleResilience, PsychologicalSymptom Burden

Identifiers

PMID38713463
PMCPMC11077392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.